Paul Tudor Jones's PFE Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 1.3 M shares of Pfizer Inc. (PFE) worth $32.41 M, representing 0.06% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 47 quarters.
Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in PFE, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2025, adding 1.16 M shares. Largest reduction occurred in Q2 2025, reducing 1.16 M shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Pfizer (PFE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Pfizer (PFE) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +1.12 M | Add 618.33% | 1.3 M | $24.90 |
| Q3 2025 | +181,213 | New Buy | 181,213 | $25.48 |
| Q2 2025 | -1.16 M | Sold Out | 0 | $0.00 |
| Q1 2025 | +1.16 M | New Buy | 1.16 M | $25.34 |
| Q4 2024 | -43,852 | Sold Out | 0 | $0.00 |
| Q3 2024 | -166,123 | Reduce 79.12% | 43,852 | $28.94 |
| Q2 2024 | +209,975 | New Buy | 209,975 | $27.98 |
| Q1 2024 | -372,691 | Sold Out | 0 | $0.00 |
| Q4 2023 | +372,691 | New Buy | 372,691 | $28.79 |
| Q3 2023 | -298,246 | Sold Out | 0 | $0.00 |
| Q2 2023 | +195,437 | Add 190.10% | 298,246 | $36.68 |
| Q1 2023 | +86,799 | Add 542.15% | 102,809 | $0.04 |
| Q4 2022 | -188,949 | Reduce 92.19% | 16,010 | $0.05 |
| Q3 2022 | +204,959 | New Buy | 204,959 | $43.76 |
| Q2 2022 | -46,169 | Sold Out | 0 | $0.00 |
| Q1 2022 | +20,243 | Add 78.08% | 46,169 | $51.77 |
| Q4 2021 | -32,143 | Reduce 55.35% | 25,926 | $59.05 |
| Q3 2021 | +36,332 | Add 167.14% | 58,069 | $43.02 |
| Q2 2021 | -25,880 | Reduce 54.35% | 21,737 | $39.15 |
| Q1 2021 | +2,306 | Add 5.09% | 47,617 | $36.23 |
| Q4 2020 | -40,892 | Reduce 47.44% | 45,311 | $36.81 |
| Q3 2020 | +19,393 | Add 29.03% | 86,203 | $36.70 |
| Q2 2020 | +66,810 | New Buy | 66,810 | $32.70 |
| Q1 2020 | -157,680 | Sold Out | 0 | $0.00 |
| Q4 2019 | +142,401 | Add 932.00% | 157,680 | $39.18 |
| Q3 2019 | +15,279 | New Buy | 15,279 | $35.93 |
| Q3 2018 | -28,230 | Sold Out | 0 | $0.00 |
| Q2 2018 | +28,230 | New Buy | 28,230 | $36.27 |
| Q1 2018 | -25,136 | Sold Out | 0 | $0.00 |
| Q4 2017 | +25,136 | New Buy | 25,136 | $36.20 |
| Q2 2017 | -6,400 | Sold Out | 0 | $0.00 |
| Q1 2017 | -4,500 | Reduce 41.28% | 6,400 | $34.22 |
| Q4 2016 | -6,300 | Reduce 36.63% | 10,900 | $32.48 |
| Q3 2016 | -4,300 | Reduce 20.00% | 17,200 | $33.90 |
| Q2 2016 | +6,900 | Add 47.26% | 21,500 | $35.21 |
| Q1 2016 | -20,300 | Reduce 58.17% | 14,600 | $29.66 |
| Q4 2015 | +6,600 | Add 23.32% | 34,900 | $32.29 |
| Q3 2015 | +12,700 | Add 81.41% | 28,300 | $31.41 |
| Q2 2015 | -1.12 M | Reduce 98.63% | 15,600 | $33.53 |
| Q1 2015 | +753,085 | Add 195.35% | 1.14 M | $34.79 |
| Q4 2014 | +279,763 | Add 264.58% | 385,500 | $31.15 |
| Q3 2014 | +89,537 | Add 552.70% | 105,737 | $29.57 |
| Q2 2014 | -858,800 | Reduce 98.15% | 16,200 | $29.69 |
| Q1 2014 | +828,753 | Add 1792.01% | 875,000 | $32.12 |
| Q4 2013 | -903,753 | Reduce 95.13% | 46,247 | $30.64 |
| Q3 2013 | +752,300 | Add 380.53% | 950,000 | $28.73 |
| Q2 2013 | +197,700 | Add 0.00% | 197,700 | $28.01 |
Paul Tudor Jones's Pfizer Investment FAQs
Paul Tudor Jones first purchased Pfizer Inc. (PFE) in Q2 2013, acquiring 197,700 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Pfizer Inc. (PFE) for 47 quarters since Q2 2013.
Paul Tudor Jones's largest addition to Pfizer Inc. (PFE) was in Q1 2025, adding 1,156,325 shares worth $29.3 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 1,301,716 shares of Pfizer Inc. (PFE), valued at approximately $32.41 M.
As of the Q4 2025 filing, Pfizer Inc. (PFE) represents approximately 0.06% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Pfizer Inc. (PFE) was 1,301,716 shares, as reported at the end of Q4 2025.